Pharmacotherapies for Cardiovascular Disease Prevention

Jennifer Ballard-Hernandez; Colleen Walsh Irwin

doi:10.1007/978-3-031-53705-9_14

Pharmacotherapies for Cardiovascular Disease Prevention

Jennifer Ballard-Hernandez
, Colleen Walsh Irwin

Office of the Dean of Nursing

VA Medical Center

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

1 Scopus citations

Abstract

Cardiovascular disease remains one of the leading causes of morbidity and mortality worldwide. Over the past several decades, the field of cardiovascular pharmacotherapy has made significant strides in the development of novel drugs and therapeutic strategies impacting cardiovascular risk reduction. This chapter will cover pharmacotherapies for cardiovascular disease risk reduction in the management of hypertension, dyslipidemia, obesity, type 2 diabetes mellitus, tobacco use, and coronary artery disease. Each topic will discuss indications, supporting clinical trial data, pharmacotherapeutics, and nursing considerations for monitoring and patient education. Overall, this chapter provides an up-to-date overview of the current state of cardiovascular pharmacotherapy in cardiovascular risk reduction.

Original language	English
Title of host publication	Preventive Cardiovascular Nursing
Subtitle of host publication	Resilience across the Lifespan for Optimal Cardiovascular Wellness
Publisher	Springer International Publishing
Pages	395-432
Number of pages	38
ISBN (Electronic)	9783031537059
ISBN (Print)	9783031537042
DOIs	https://doi.org/10.1007/978-3-031-53705-9_14
State	Published - Jan 1 2024

Access to Document

10.1007/978-3-031-53705-9_14

Cite this

@inbook{55e41418885c477ab8b2881c325edd8a,

title = "Pharmacotherapies for Cardiovascular Disease Prevention",

abstract = "Cardiovascular disease remains one of the leading causes of morbidity and mortality worldwide. Over the past several decades, the field of cardiovascular pharmacotherapy has made significant strides in the development of novel drugs and therapeutic strategies impacting cardiovascular risk reduction. This chapter will cover pharmacotherapies for cardiovascular disease risk reduction in the management of hypertension, dyslipidemia, obesity, type 2 diabetes mellitus, tobacco use, and coronary artery disease. Each topic will discuss indications, supporting clinical trial data, pharmacotherapeutics, and nursing considerations for monitoring and patient education. Overall, this chapter provides an up-to-date overview of the current state of cardiovascular pharmacotherapy in cardiovascular risk reduction.",

author = "Jennifer Ballard-Hernandez and Irwin, \{Colleen Walsh\}",

note = "Publisher Copyright: {\textcopyright} The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2024.",

year = "2024",

month = jan,

day = "1",

doi = "10.1007/978-3-031-53705-9\_14",

language = "English",

isbn = "9783031537042",

pages = "395--432",

booktitle = "Preventive Cardiovascular Nursing",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Pharmacotherapies for Cardiovascular Disease Prevention

AU - Ballard-Hernandez, Jennifer

AU - Irwin, Colleen Walsh

N1 - Publisher Copyright: © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2024.

PY - 2024/1/1

Y1 - 2024/1/1

N2 - Cardiovascular disease remains one of the leading causes of morbidity and mortality worldwide. Over the past several decades, the field of cardiovascular pharmacotherapy has made significant strides in the development of novel drugs and therapeutic strategies impacting cardiovascular risk reduction. This chapter will cover pharmacotherapies for cardiovascular disease risk reduction in the management of hypertension, dyslipidemia, obesity, type 2 diabetes mellitus, tobacco use, and coronary artery disease. Each topic will discuss indications, supporting clinical trial data, pharmacotherapeutics, and nursing considerations for monitoring and patient education. Overall, this chapter provides an up-to-date overview of the current state of cardiovascular pharmacotherapy in cardiovascular risk reduction.

AB - Cardiovascular disease remains one of the leading causes of morbidity and mortality worldwide. Over the past several decades, the field of cardiovascular pharmacotherapy has made significant strides in the development of novel drugs and therapeutic strategies impacting cardiovascular risk reduction. This chapter will cover pharmacotherapies for cardiovascular disease risk reduction in the management of hypertension, dyslipidemia, obesity, type 2 diabetes mellitus, tobacco use, and coronary artery disease. Each topic will discuss indications, supporting clinical trial data, pharmacotherapeutics, and nursing considerations for monitoring and patient education. Overall, this chapter provides an up-to-date overview of the current state of cardiovascular pharmacotherapy in cardiovascular risk reduction.

UR - https://www.scopus.com/pages/publications/85207200798

U2 - 10.1007/978-3-031-53705-9_14

DO - 10.1007/978-3-031-53705-9_14

M3 - Chapter

AN - SCOPUS:85207200798

SN - 9783031537042

SP - 395

EP - 432

BT - Preventive Cardiovascular Nursing

PB - Springer International Publishing

ER -

Pharmacotherapies for Cardiovascular Disease Prevention

Abstract

Access to Document

Other files and links

Fingerprint

Cite this